Denali therapeutics inc posts qtrly loss per share of $0.56

Denali therapeutics reports full year 2019 financial results and business highlights.qtrly loss per share $0.56.qtrly collaboration revenue $4.7 million versus $125.7 million.q4 earnings per share view $-0.58 -- refinitiv ibes data.

DNLI Ratings Summary

DNLI Quant Ranking